Case Detail

Novartis Pharmaceuticals Corp. v. Fussman
On October 7, 2013, the U.S. Supreme Court issued an order declining to review an appeals court decision that permits a private plaintiff suing under state law to impose punishment, in the form of punitive damages, on a prescription drug manufacturer who fully satisfied the FDAs rigorous approval and labeling requirements. The order was a setback for WLF, which filed a brief in the case urging discretionary review. WLF argued that such punitive damages claims are impliedly preempted by federal law because they stand as an obstacle to the accomplishment of the goals of Congress and the FDA. In its brief, WLF also argued that allowing punitive damages award under North Carolina law undermines federal law by calling into question FDAs decisions enforcement specific product labels. WLFs brief sought to distinguish the instant case from Wyeth v. Levine, an earlier Supreme Court preemption case decided in 2009 that involved an award of compensatory damages.
Case Status:
More Information and Downloads:
6/27/2013: Download the Brief

  • Welcome to the Washington Legal Foundation
  • 2009 Massachusetts Ave., NW
    Washington, DC 20036
  • info@wlf.org  |  ph. 202-588-0302
    ©2018 WLF All Rights Reserved